Evolution of Biologic Drug Discovery and Business Models

The chapter delves into the evolution of a company in the biologic drug discovery industry, emphasizing the shift towards next-generation biologics and the development of unique engineering solutions for different protein modalities. It also explores a business model where companies collaborate with the speakers to produce targeted antibodies or biologics through a fee-for-service approach, involving milestones and royalties for successful outcomes.